These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 27858163)
1. Expression of PIWIL3 in primary and metastatic melanoma. Gambichler T; Kohsik C; Höh AK; Lang K; Käfferlein HU; Brüning T; Stockfleth E; Stücker M; Dreißigacker M; Sand M J Cancer Res Clin Oncol; 2017 Mar; 143(3):433-437. PubMed ID: 27858163 [TBL] [Abstract][Full Text] [Related]
2. Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences. Dai B; Cai X; Kong YY; Yang F; Shen XX; Wang LW; Kong JC Hum Pathol; 2013 Aug; 44(8):1472-8. PubMed ID: 23528861 [TBL] [Abstract][Full Text] [Related]
4. Molecular oncogene markers and their significance in cutaneous malignant melanoma. Konstadoulakis MM; Vezeridis M; Hatziyianni E; Karakousis CP; Cole B; Bland KI; Wanebo HJ Ann Surg Oncol; 1998; 5(3):253-60. PubMed ID: 9607628 [TBL] [Abstract][Full Text] [Related]
5. Independent prognostic importance of vascular invasion in nodular melanomas. Straume O; Akslen LA Cancer; 1996 Sep; 78(6):1211-9. PubMed ID: 8826942 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients. Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500 [TBL] [Abstract][Full Text] [Related]
7. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Kanitakis J; Narvaez D; Claudy A Melanoma Res; 2002 Jun; 12(3):241-4. PubMed ID: 12140380 [TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of primary cutaneous melanoma and clinical outcome. Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A; J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783 [TBL] [Abstract][Full Text] [Related]
9. Factors predicting survival in thick melanoma: Do all thick melanomas have the same prognosis? Han D; Han G; Morrison S; Leong SP; Kashani-Sabet M; Vetto J; White R; Schneebaum S; Pockaj B; Mozzillo N; Sondak VK; Zager JS Surgery; 2020 Sep; 168(3):518-526. PubMed ID: 32669204 [TBL] [Abstract][Full Text] [Related]
11. Value of anatomic site, histology and clinicopathological parameters for prediction of lymph node metastasis and overall survival in head and neck melanomas. Ettl T; Irga S; Müller S; Rohrmeier C; Reichert TE; Schreml S; Gosau M J Craniomaxillofac Surg; 2014 Jul; 42(5):e252-8. PubMed ID: 24216129 [TBL] [Abstract][Full Text] [Related]
12. Beta 1 integrin expression in malignant melanoma predicts occult lymph node metastases. Hieken TJ; Ronan SG; Farolan M; Shilkaitis AL; Kim DK; Das Gupta TK Surgery; 1995 Oct; 118(4):669-73; discussion 673-5. PubMed ID: 7570321 [TBL] [Abstract][Full Text] [Related]
13. Disease progression in patients with thin cutaneous melanomas (tumour thickness < or = 0.75 mm): clinical and epidemiological data from the Tumour Center Munich 1977-98. Schmid-Wendtner MH; Baumert J; Eberle J; Plewig G; Volkenandt M; Sander CA Br J Dermatol; 2003 Oct; 149(4):788-93. PubMed ID: 14616371 [TBL] [Abstract][Full Text] [Related]
14. Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer. Huang L; David O; Cabay RJ; Valyi-Nagy K; Macias V; Zhong R; Wenig B; Feldman L; Weichselbaum R; Spiotto MT Clin Cancer Res; 2019 Mar; 25(6):1795-1808. PubMed ID: 30573692 [TBL] [Abstract][Full Text] [Related]
15. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748 [TBL] [Abstract][Full Text] [Related]
16. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Dadras SS; Paul T; Bertoncini J; Brown LF; Muzikansky A; Jackson DG; Ellwanger U; Garbe C; Mihm MC; Detmar M Am J Pathol; 2003 Jun; 162(6):1951-60. PubMed ID: 12759251 [TBL] [Abstract][Full Text] [Related]
17. MiRNAs as Potential Prognostic Biomarkers for Metastasis in Thin and Thick Primary Cutaneous Melanomas. Valentini V; Zelli V; Gaggiano E; Silvestri V; Rizzolo P; Bucalo A; Calvieri S; Grassi S; Frascione P; Donati P; Soda G; Ottini L; Richetta AG Anticancer Res; 2019 Aug; 39(8):4085-4093. PubMed ID: 31366492 [TBL] [Abstract][Full Text] [Related]
18. Uveal Melanoma Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis. Szalai E; Wells JR; Ward L; Grossniklaus HE Ophthalmology; 2018 Feb; 125(2):203-209. PubMed ID: 28823399 [TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node biopsy for cutaneous melanoma: a propos of 144 cases. Konofaos P; Karypidis D; Chrisostomidis C; Kostopoulos E; Champsas G; Papadopoulos O J BUON; 2014; 19(1):263-72. PubMed ID: 24659674 [TBL] [Abstract][Full Text] [Related]
20. Role of Elevated Bezrookove V; Nosrati M; Miller JR; De Semir D; Dar AA; Vosoughi E; Vaquero E; Sucker A; Lazar AJ; Gershenwald JE; Davies MA; Schadendorf D; Kashani-Sabet M Clin Cancer Res; 2018 Sep; 24(17):4119-4125. PubMed ID: 29776954 [No Abstract] [Full Text] [Related] [Next] [New Search]